Copyright
©The Author(s) 2019.
World J Gastroenterol. May 21, 2019; 25(19): 2365-2372
Published online May 21, 2019. doi: 10.3748/wjg.v25.i19.2365
Published online May 21, 2019. doi: 10.3748/wjg.v25.i19.2365
Table 1 The baseline characteristics of patients
Variables | All (n = 20) |
Age, yr | 68.6 ± 8.4 |
Gender, male : female | 19:1 |
BMI, kg/m2 | 22.2 ± 4.2 |
ECOG PS, 0:1: | 18:2 |
Etiology, HBV:HCV:alcohol:others | 7:7:3:3 |
AST, IU/L | 52.2 ± 38.1 |
ALT, IU/L | 45.1 ± 26.3 |
T.Bil, mg/dL | 0.7 ± 0.4 |
Alb, g/dL | 3.4 ± 0.5 |
PT, % | 82.2 ± 15.2 |
Plt, × 104/μL | 19.7 ± 6.1 |
Child–Pugh score, 5:6 points | 8:12 |
Median AFP, ng/mL (range) | 268 (4.5-53000) |
Intrahepatic tumor size, cm | 6.6 ± 6.3 |
Number of intrahepatic tumors, single : multiple | 3:17 |
Portal vein invasion, n (%) | 9 (45.0) |
Extrahepatic metastasis, n (%) | 15 (75.0) |
Previous treatment, n (%) | 19 (95.0) |
Initial dose of lenvatinib, 8:12 mg/d | 16:4 |
Table 2 Distribution of changes in time-intensity curve parameters in tumors from day 0 to day 7 for 20 hepatocellular carcinoma patients according to modified Response Evaluation Criteria in Solid Tumors response at 2 mo
Responders (n = 9) | Non-responders (n = 11) | |||
Day 0 | Day 7 | Day 0 | Day 7 | |
Slope | 1.51 [1.31, 1.68] | 1.09 [0.84, 1.23] | 1.52 [1.22, 1.62] | 1.33 [0.86, 1.71] |
P value | 0.018 | 0.511 | ||
TTP | 10.56 [9.33, 12.13] | 12.43 [11.94, 13.94] | 11.02 [8.53, 12.51] | 11.84 [10.15, 13.82] |
P value | 0.003 | 0.247 | ||
AUC | 266.51 [225.38, 296.67] | 156.44 [123.05, 178.91] | 258.14 [191.61, 299.51] | 229.65 [176.10, 269.50] |
P value | 0.001 | 0.322 |
Table 3 The performance characteristics of the rate of change of time-intensity curve parameters for the prediction of responders
Slope (95%CI) | TTP (95%CI) | AUC (95%CI) | |
AUROC | 0.818 (0.602-0.944) | 0.869 (0.728-0.975) | 0.939 (0.812-0995) |
Cut-off value (%) | -11.765 | +9.495 | -25.714 |
Sensitivity | 0.889 (0.540-0.978) | 0.889 (0.540-0.978) | 0.896 (0.616-0.989) |
Specificity | 0.545 (0.304-0.786) | 0.818 (0.510-0.917) | 0.909 (0.648-0.995) |
PPV | 0.615 (0.583-0.793) | 0.800 (0.611-0.907) | 0.833 (0.727-0.918) |
NPV | 0.857 (0.731-0.922) | 0.878 (0.741-0.962) | 0.900 (0.747-0.992) |
- Citation: Kuorda H, Abe T, Fujiwara Y, Okamoto T, Yonezawa M, Sato H, Endo K, Oikawa T, Sawara K, Takikawa Y. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma. World J Gastroenterol 2019; 25(19): 2365-2372
- URL: https://www.wjgnet.com/1007-9327/full/v25/i19/2365.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i19.2365